Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma. Chen Q, Sun Q, Zhang J, Li B, et al. PLoS One 2024;19:e0295090.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chen Q, Sun Q, Zhang J, Li B, et al. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma. PLoS One 2024;19:e0295090.
PMID: 38437209